RxDoctor Payments Data

Hilary Shapiro

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1811382815

Payments from drug & device makers

$988in general payments, 2019–2025

Across 16 payments — averaging $61.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$709
  • Impulse Dynamics (USA) Inc.$150
  • Kiniksa Pharmaceuticals International, PLC$45
  • Kestra Medical Technology Services, Inc.$27
  • Scpharmaceuticals Inc.$21
  • AstraZeneca$21
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 5th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$141,458
Medicare patients
293
Services billed
1,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin86$91,971
EntrestoSacubitril/Valsartan102$85,243
EliquisApixaban65$62,083
FarxigaDapagliflozin Propanediol34$38,529
TrulicityDulaglutide16$14,169
CorlanorIvabradine Hcl12$7,033
Valganciclovir Hcl24$2,437
Bumetanide76$2,170
Eplerenone17$1,462
Rosuvastatin Calcium68$1,290
Ursodiol14$1,221
Tacrolimus11$1,129
Metoprolol Succinate58$917
Potassium Chloride44$898
Carvedilol104$730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$21$38,52934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →